• 1. 華中科技大學(xué)附屬協(xié)和醫(yī)院肝膽外科（武漢430022）;;
  • 2. 山東省勝利油田中心醫(yī)院（山東東營257034）;

【摘要】目的探討β-連環(huán)蛋白異常表達和c-myc陽性表達在肝門部膽管癌發(fā)生、發(fā)展過程中的作用及其機理。
方法應(yīng)用免疫組織化學(xué)SP法對42例肝門部膽管癌及10例膽管良性病變組織中的β-連環(huán)蛋白和c-myc蛋白進行檢測，并結(jié)合臨床資料進行分析。
結(jié)果β-連環(huán)蛋白在10例膽管良性病變組織中均呈正常表達，且c-myc均呈陰性表達； 而在42例膽管癌患者中30例癌組織細胞胞漿內(nèi)的β-連環(huán)蛋白的異常表達率明顯高于膽管良性病變組織，且異常表達率與肝門部膽管癌的淋巴結(jié)轉(zhuǎn)移顯著相關(guān)（P＜0.05），而與肝門膽管癌大小、分化程度和侵襲狀況無關(guān)（P gt;0.05）。膽管癌中c-myc表達陽性率與肝門膽管癌的大小、侵襲狀況及淋巴結(jié)轉(zhuǎn)移無關(guān)（P gt;0.05），而與肝門部膽管癌的分化程度密切相關(guān)（P＜0.05）。β-連環(huán)蛋白異常表達與 c-myc陽性表達在肝門部膽管癌中呈顯著的正相關(guān)性（r=0.324,P＜0.01）。
結(jié)論肝門部膽管癌細胞中存在β-連環(huán)蛋白異常表達和c-myc蛋白陽性表達的現(xiàn)象，與膽管癌的一些生物學(xué)行為密切相關(guān)。β-連環(huán)蛋白的異常表達可能是肝門部膽管癌轉(zhuǎn)移的分子機理之一。

引用本文： 鄭啟昌,陳海波,左克強,張勇. β-連環(huán)蛋白在肝門部膽管癌中的表達及其與c-myc表達的關(guān)系. 中國普外基礎(chǔ)與臨床雜志, 2005, 12(1): 67-70. doi: 復(fù)制

1. Jawhari AU, Farthing MJ, Pignatelli M. The Ecadherin/epidermal growth factor receptor interaction: a hypothesis of reciprocal and reversible control of intercellular adhesion and cell proliferation [Ｊ]. J Pathol， 1999； 187(2)∶155.
2. He TC, Sparks AB, Rago C, et al. Identification of cmyc as a target of the APC pathway [Ｊ]. Science，1998； 281（5）∶ 1509.
3. Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the Ecadherincatenin complex in gastric cancer: relationship with patient survival [Ｊ]. Gastroenterology, 1997； 112（4）∶46.
4. Fromowitz FB, Steinbook ML, Lautin EM, et al. ras p21 expression in the progression of breast cancer [Ｊ]. Hum Pathol， 1987； 18(12)∶1268.
5. Tetsu O, McCormick F. betacatebub regulates expression of cyclinD1 in colon carcinoma cells [Ｊ]. Nature， 1999； 398(6726)∶422.
6. Alman BA, Li C, Pajerski ME, et al.Increased betacatenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors) [Ｊ]. Am J Pathol，1997； 151(2)∶329.
7. Kishida S, Yamamoto H,Ikeda S, et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of betacatenin [Ｊ]. J Biol Chem, 1998； 273(18)∶10823.
8. 臧桐，莊立巖，張志文， 等. β連環(huán)蛋白基因在腎癌中的表達及其突變分析 [Ｊ].中華泌尿外科雜志,2000； 21(6)∶328.
9. Ougolkov A, Yamashita K, Bilim V, et al. Abnormal expression of Ecadherin, betacatenin, and cerbB2 in advanced gastric cancer: its association with liver metastasis [Ｊ]. Int J Colorectal Dis， 2003； 18(2)∶160.
  1. 1. Jawhari AU, Farthing MJ, Pignatelli M. The Ecadherin/epidermal growth factor receptor interaction: a hypothesis of reciprocal and reversible control of intercellular adhesion and cell proliferation [Ｊ]. J Pathol， 1999； 187(2)∶155.
  2. 2. He TC, Sparks AB, Rago C, et al. Identification of cmyc as a target of the APC pathway [Ｊ]. Science，1998； 281（5）∶ 1509.
  3. 3. Jawhari A, Jordan S, Poole S, et al. Abnormal immunoreactivity of the Ecadherincatenin complex in gastric cancer: relationship with patient survival [Ｊ]. Gastroenterology, 1997； 112（4）∶46.
  4. 4. Fromowitz FB, Steinbook ML, Lautin EM, et al. ras p21 expression in the progression of breast cancer [Ｊ]. Hum Pathol， 1987； 18(12)∶1268.
  5. 5. Tetsu O, McCormick F. betacatebub regulates expression of cyclinD1 in colon carcinoma cells [Ｊ]. Nature， 1999； 398(6726)∶422.
  6. 6. Alman BA, Li C, Pajerski ME, et al.Increased betacatenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors) [Ｊ]. Am J Pathol，1997； 151(2)∶329.
  7. 7. Kishida S, Yamamoto H,Ikeda S, et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of betacatenin [Ｊ]. J Biol Chem, 1998； 273(18)∶10823.
  8. 8. 臧桐，莊立巖，張志文， 等. β連環(huán)蛋白基因在腎癌中的表達及其突變分析 [Ｊ].中華泌尿外科雜志,2000； 21(6)∶328.
  9. 9. Ougolkov A, Yamashita K, Bilim V, et al. Abnormal expression of Ecadherin, betacatenin, and cerbB2 in advanced gastric cancer: its association with liver metastasis [Ｊ]. Int J Colorectal Dis， 2003； 18(2)∶160.